Importance Approximately one-third of cancer drugs are approved based on response rate
(RR)—the percentage of patients whose tumors shrink beyond an arbitrary threshold …

Objectives The objective of the study was to outline key considerations for general clinical
readers when critically evaluating publications on platform trials and for researchers when …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

Abstract Background In July 2018, the FDA first published a table listing all surrogate
measures that it has used, and may accept for future use, in regulatory approval. However …

Significant progress has been made toward improving the care of older adults with cancer.
As described elsewhere in this Special Series, the evidence base in geriatric oncology has …

Mb. The underlying data from KEYNOTE-158 suggest the cut off is arbitrary and capricious.
Below 10 mut/Mb, pembrolizumab's response rate (RR) is 6.7%. From 10 to 13 mut/Mb, the …

Important breakthroughs in medical treatments have improved outcomes for patients
suffering from several types of cancer. However, many oncological treatments approved by …

Progression-free survival refers to the time from randomisation or initiation of treatment to the
occurrence of disease progression or death. Disease progression is defined by the …

Objective To examine the design characteristics, risk of bias, and reporting adequacy of
pivotal randomised controlled trials of cancer drugs approved by the European Medicines …

Importance Of approximately 9 million patients with cancer in China in 2020, more than half
were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused …